Macrogenics (MGNX) Revenue Growth (1y) (2013 - 2026)
Macrogenics (MGNX) Revenue Growth (1y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,741.39 Bn | 66,741.11 Bn | - | - |
| 2 | Nanobiotix | 1,912.31 Bn | 1,912.25 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 467.15 Bn | 462.36 Bn | 1.35 Bn | 35.46% |
| 5 | Vertex Pharmaceuticals | 123.00 Bn | 115.76 Bn | 2.59 Bn | 7.82% |
| 6 | Regeneron Pharmaceuticals | 70.22 Bn | 61.47 Bn | 3.31 Bn | 19.04% |
| 7 | Belite Bio | 62.93 Bn | 62.93 Bn | - | - |
| 8 | Argenx Se | 55.76 Bn | 50.57 Bn | 1.41 Bn | 64.03% |
| 9 | Alnylam Pharmaceuticals | 37.70 Bn | 34.69 Bn | 959.66 Mn | 96.43% |
| 10 | Macrogenics | 249.99 Mn | 183.48 Mn | - | 57.48% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 57.48% |
| Dec 31, 2025 | 3.07% |
| Sep 30, 2025 | -34.21% |
| Jun 30, 2025 | 105.99% |
| Mar 31, 2025 | 44.90% |
| Dec 31, 2024 | 273.13% |
| Sep 30, 2024 | 964.81% |
| Jun 30, 2024 | -17.81% |
| Mar 31, 2024 | -62.83% |
| Dec 31, 2023 | -85.33% |
| Sep 30, 2023 | -75.09% |
| Jun 30, 2023 | -49.49% |
| Mar 31, 2023 | 120.66% |
| Dec 31, 2022 | 416.71% |
| Sep 30, 2022 | 166.47% |
| Jun 30, 2022 | -15.44% |
| Mar 31, 2022 | -34.24% |
| Dec 31, 2021 | -29.26% |
| Sep 30, 2021 | -14.19% |
| Jun 30, 2021 | 51.83% |